Ironwood Pharmaceuticals
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 days.
- Recent price momentum is +30.9% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 9.0% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation A
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 5.2x | Better than 96% |
| Forward P/E | 3.6x | Better than 99% |
| Price / Sales | 2.0x | Better than 57% |
| P/E vs own 5-yr range | 55th pctl | Better than 55% |
Growth F
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | -10.3% | Better than 6% |
| Net income CAGR (3Y) | -48.4% | Better than 4% |
| Free cash flow CAGR (3Y) | -22.6% | Better than 16% |
Profitability B-
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 100.0% | Better than 99% |
| Operating margin | 40.1% | Better than 95% |
| Net margin | 8.1% | Better than 54% |
| Return on equity | -654.9% | Better than 1% |
| Return on invested capital | -139.2% | Better than 1% |
Momentum A-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 9.6% | Better than 90% |
| 6-month return | 19.9% | Better than 83% |
| 12-month return (ex latest month) | 13.0% | Better than 50% |
| Distance below 52-week high | 18.7% | Better than 63% |
Financial Health C
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 1.1x | Better than 26% |
| Debt to assets | 150.6% | Better than 1% |
| Interest coverage | 3.1x | Better than 46% |
| Free cash flow / net income | 528.8% | Better than 93% |
Analyst View N/A
What the Street thinks: share of Buy ratings and upside to the average target.
Not enough data to grade this factor.
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 4.71
- Open
- 4.66
- Day range
- 4.65 - 4.87
- Avg price
- 4.73
- Volume
- 3.02M
- Turnover
- 14.28M
- Turnover ratei
- 2.22%
- Volume ratioi
- 1.06
- Amplitudei
- 4.67%
- 52-week rangei
- 2.95 - 5.78
Valuation
- P/Ei
- 31.33
- P/E (TTM)i
- 5.22
- P/Bi
- -8.01
- EPSi
- 0.15
- Book value / shi
- -0.59
- Net profit
- 24.83M
- Net assets
- -97.18M
Share structure
- Market cap
- 778.09M
- Float capi
- 639.23M
- Shares out
- 165.55M
- Float sharesi
- 136.01M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- --
18.7% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-5.44M net over the window
Short interest
- Shares short
- 14.86M
- % of floati
- 8.99%
- Days to coveri
- 9.84
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Ironwood Pharmaceuticals (IRWD)?
Ironwood Pharmaceuticals last traded at 4.70. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Ironwood Pharmaceuticals's market cap?
About 778.09M.
What is the P/E ratio of Ironwood Pharmaceuticals?
The trailing twelve-month P/E is 5.22. The Valuation tab shows it against the stock's own five-year range.
Does Ironwood Pharmaceuticals pay a dividend?
Ironwood Pharmaceuticals does not currently pay a regular dividend.
Is Ironwood Pharmaceuticals a buy according to analysts?
The consensus of 1 analysts is a Buy rating, with an average 12-month price target of 6.00, which implies 27.7% upside from the current price. This is not investment advice.
What is Ironwood Pharmaceuticals's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Ironwood Pharmaceuticals a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 20:01:04 · For reference only, not investment advice and not tailored to your situation.
Ironwood Pharmaceuticals discussion 0 comments